KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.

Mazin Abdelghany, Fang Yu, Stephen Rennard, Yeongjin Gwon

PLoS One 21(4) e0346878

PMID41990093
PMCIDPMC13086435
DOI10.1371/journal.pone.0346878
发表日期2026-04-16
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:森林图/亚组分析图;Fig 3:森林图/亚组分析图;Fig 4:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Though Bayesian methods are flexible, intuitive, and readily incorporated into clinical decision-making, with particular utility when prior information is available, they remain underutilized in the analysis of clinical trials. METHODS: In PINETREE, a Phase 3 randomized controlled trial (RCT) of remdesivir (RDV) for the treatment of outpatients with COVID-19 at high risk of severe disease, the primary outcome of COVID-19-related hospitalization or all-cause death was reanalyzed using a range of reference and data-driven priors. Posterior probability distributions were used to calculate the probability that the estimated hazard ratio (HR) was below a range of clinically meaningful specified thresholds and to estimate the treatment effect and its 95% credible interval (CrI). RESULTS: Under a minimally informative prior, the posterior probability of an estimated HR less than 1 for COVID-19-related hospitalization or all-cause death was 1 with a posterior median HR 0.13 and 95% CrI 0.02-0.47, recovering the frequentist estimates. Moreover, estimated posterior probability distributions, posterior median HRs, and 95% CrIs were robust across a range of both reference and data-driven prior choices, indicating the strength of the trial data. Lastly, using priors that incorporate historical RCT data, precision of the estimated posterior median HR and 95% CrI was improved over naïve, frequentist estimates. CONCLUSIONS: In a Bayesian reanalysis of the PINETREE trial, there was a 98.9% or greater probability that treatment with RDV reduced the risk of COVID-19-related hospitalization or all-cause death across all prior probability distributions.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Patient disposition.
非 KM Figure
Fig 2Reference and data-driven prior distributions for the HR of the treatment effect of RDV on COVID-19–related hospitalization or all-cause death. HR = hazard ratio; RDV = remdesivir; DAA = direct-acting antiviral. The vertical dotted reference line indicates the no treatment effect threshold (i.e., HR = 1). The distributions in the legend (e.g., N(0, 3)) indicate a normal distribution on the logarithm of the hazard ratio with the x-axis labels exponentiated for convenience. (A) Five reference priors were selected to represent a range of beliefs of the treatment effect of RDV on COVID-19–related hospitalization or all-cause death (see Table 1 for rationale for each distribution). (B) Three data-driven priors based on 9 previous RCTs (see Methods for details).
非 KM Figure
Fig 3Prior (orange) and posterior (purple) distributions for the five reference priors for the HR of the treatment effect of RDV on COVID-19–related hospitalization or all-cause death. HR = hazard ratio; RDV = remdesivir; AUC = area under the curve. Orange lines indicate the reference prior probability distribution. Purple lines indicate the posterior probability distribution. The vertical dotted reference line indicates the no treatment effect threshold (i.e., HR = 1). Probabilities for HRs less than a specific threshold are calculated as the area under the posterior probability curve to the left of that threshold (e.g., panel F ). Alt text: Graphs depicting posterior distribution, which represents the effects of incorporating the trial data into each of the five reference priors. The final panel shows a shaded region depicting the area under the curve, which represents the posterior probability for the hazard ratio being less than a specific threshold. Reference prior distributions are shown in orange, and the posterior distributions are shown in purple.
非 KM Figure
Fig 4Prior (orange) and posterior (purple) distributions for the three data-driven priors for the HR of the treatment effect of RDV on COVID-19–related hospitalization or all-cause death. HR = hazard ratio; RDV = remdesivir; DAA = direct-acting antiviral. Orange lines indicate the data-driven prior probability distribution. Purple lines indicate the posterior probability distribution. The vertical dotted reference line indicates the no treatment effect threshold (i.e., HR = 1). Probabilities for HRs less than a specific threshold are calculated as the area under the posterior probability curve to the left of that threshold (see Fig 3F for example). (A) Mixture prior, all trials: the posterior probability reallocates the mode of the prior probability distribution most consistent with the PINETREE data. (B) Mixture prior, DAA trials: the variance of the posterior probability density decreases representing increased precision of the effect estimate and a narrower 95% credible interval. (C) Mixture prior: non-DAA trials: The posterior probability density is shifted to the right (towards larger HRs) by the large prior probability mass at HRs between 0.5 and 1. Alt text: Graphs depicting posterior distribution, which represents the effects of incorporating the trial data into each of the three data-driven priors. Reference prior distributions are shown in orange, and the posterior distributions are shown in purple.
非 KM Figure